Is Illumina Inc (ILMN) a risky stock?
As of July 21, 2026, Clavix grades Illumina Inc (ILMN) B- for risk, a composite score of 63 out of 100 on an A+ to F scale, which puts ILMN in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ILMN's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ILMN scores on each, as of July 21, 2026.
What's moving ILMN's risk right now
Company-specific signals Clavix flags behind ILMN's current grade, drawn from recent news and filings as of July 21, 2026.
A German court ruled against Illumina in a patent fight with Element Biosciences, putting Illumina's sequencing sales in Germany at risk of restrictions and exposing it to possible damages or redesign costs.
rating firm Wall Street Zen downgraded Illumina, citing reduced confidence in the stock's near-term upside, which could weigh on investor news signal.
Illumina is adding new AI drug discovery companies to its Billion Cell Atlas program, building a genomic database business that could open an additional source of revenue beyond sequencing instruments.
What a B- grade means
On the Clavix A+ to F scale, ILMN's composite of 63 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ILMN or any security. Grades are risk indicators, not predictions of return. Data may be delayed.